Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Neuronal and Glial Csf Biomarkers in Multiple Sclerosis: A Systematic Review and Meta-Analysis Publisher Pubmed



Momtazmanesh S1, 2, 3 ; Shobeiri P1, 2 ; Saghazadeh A2, 3 ; Teunissen CE4 ; Burman J5 ; Szalardy L6 ; Klivenyi P6 ; Bartos A7 ; Fernandes A8 ; Rezaei N3, 9, 10
Authors
Show Affiliations
Authors Affiliations
  1. 1. School of Medicine, Tehran University of Medical Sciences (TUMS), Children's Medical Center Hospital, Dr. Qarib St, Tehran, 14194, Iran
  2. 2. Systematic Review and Meta-Analysis Expert Group (SRMEG), Universal Scientific Education and Research Network (USERN), Tehran, Iran
  3. 3. Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran, Iran
  4. 4. Neurochemistry Laboratory, Department of Clinical Chemistry, Location VUmc Boelelaan 1117, PK 2 BR 141, Amsterdam, 1081, HV, Netherlands
  5. 5. Department of Neuroscience, Uppsala University Hospital, Uppsala, 75185, Sweden
  6. 6. Department of Neurology, Faculty of Medicine, Albert Szent-Gyorgyi Clinical Center, Semmelweis u. 6, Szeged, 6725, Hungary
  7. 7. Department of Neurology, Third Faculty of Medicine, Charles University, Ruska 87, Prague, 10000, Czech Republic
  8. 8. Department of Pharmacological Sciences and Medicines, Faculty of Pharmacy, Universidade de Lisboa, Avenida Professor Gama Pinto, Lisbon, 1649-003, Portugal
  9. 9. Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  10. 10. Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran

Source: Reviews in the Neurosciences Published:2021


Abstract

Multiple sclerosis (MS) is a neurodegenerative disease associated with inflammatory demyelination and astroglial activation, with neuronal and axonal damage as the leading factors of disability. We aimed to perform a meta-analysis to determine changes in CSF levels of neuronal and glial biomarkers, including neurofilament light chain (NFL), total tau (t-tau), chitinase-3-like protein 1 (CHI3L1), glial fibrillary acidic protein (GFAP), and S100B in various groups of MS (MS versus controls, clinically isolated syndrome (CIS) versus controls, CIS versus MS, relapsing-remitting MS (RRMS) versus progressive MS (PMS), and MS in relapse versus remission. According to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses, we included 64 articles in the meta-analysis, including 4071 subjects. For investigation of sources of heterogeneity, subgroup analysis, meta-regression, and sensitivity analysis were conducted. Meta-analyses were performed for comparisons including at least three individual datasets. NFL, GFAP, t-tau, CHI3L1, and S100B were higher in MS and NFL, t-tau, and CHI3L1 were also elevated in CIS patients than controls. CHI3L1 was the only marker with higher levels in MS than CIS. GFAP levels were higher in PMS versus RRMS, and NFL, t-tau, and CHI3L1 did not differ between different subtypes. Only levels of NFL were higher in patients in relapse than remission. Meta-regression showed influence of sex and disease severity on NFL and t-tau levels, respectively and disease duration on both. Added to the role of these biomarkers in determining prognosis and treatment response, to conclude, they may serve in diagnosis of MS and distinguishing different subtypes. © 2021 Walter de Gruyter GmbH, Berlin/Boston 2021.
Other Related Docs